Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)

Trial Profile

Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms BBP
  • Most Recent Events

    • 02 Jun 2017 Results assessing relation between tumour progression and exercise behaviour presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.
    • 27 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top